WilmerHale has advised Dyne Therapeutics. Cooley LLP has advised the underwriters. Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on genetically driven neuromuscular diseases, has...
Dyne Therapeutics Closes $431.4 Million Upsized Public Offering of Common Stock
Dyne Therapeutics Completes $402.5 Million Public Offering of Common Stock
WilmerHale has advised Dyne Therapeutics. Cooley LLP has advised the underwriters. Dyne Therapeutics, Inc., a clinical-stage company specializing in therapies for genetically driven neuromuscular diseases, has...
Dyne Therapeutics Launches $230 Million Common Stock Offering
WilmerHale has advised Dyne Therapeutics on the offerinf, and Wolf, Greenfield & Sacks, P.C. has represented Dyne Therapeutics as intellectual property counsel, while Cooley LLP has...
Dyne Therapeutics Secures $275 Million Debt Financing Facility
WilmerHale has represented Dyne Therapeutics, Inc. on the transaction. Dyne Therapeutics, Inc. has completed a senior secured debt financing totaling $275 million with Hercules Capital, Inc....
Dyne Therapeutics’ $374.3 Million Common Stock Offering
Wilmer Cutler Pickering Hale and Dorr advised Dyne Therapeutics, Inc. on the offering, and Cooley advised the underwriters. Dyne Therapeutics, Inc. (Nasdaq:DYN) announced the closing of...
Dyne Therapeutics’ $345 Million Common Stock Offering
Wilmer Cutler Pickering Hale and Dorr advised Dyne Therapeutics, Inc., and Cooley advised the underwriters. Dyne Therapeutics, Inc. (Nasdaq:DYN) (“Dyne”) announced the closing of an underwritten public offering...